Abstract
An important aspect of the ComprehensiveIn VitroProarrhythmia Assay (CiPA) proposal is the use of human stem cell-derived cardiomyocytes and the confirmation of their predictive power in drug safety assays. The benefits of this cell source are clear; drugs can be testedin vitroon human cardiomyocytes, with patient-specific genotypes if needed, and
... read more